Results 71 to 80 of about 16,542 (247)

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

, 2021
Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained ...
Boguniewicz, M, Chao, J, Simpson, EL, Kataoka, Y, Chen, Z, Bagousse, GBL, Rossi, AB, Foley, P, Silverberg, JI, De Bruin-Weller, MS, Shumel, B   +10 more
core   +1 more source

Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Lichen amyloidosis (LA) is a chronic, pruritic dermatosis with papillary dermal amyloid deposition. Standard therapies often fail, and most reports of dupilumab in LA involve patients with concomitant atopic dermatitis. We report a 32‐year‐old man with refractory, non‐atopic LA who had failed topical corticosteroids, tacrolimus, phototherapy ...
Sohrab Elahwiesy, Franziska Jochims, Manfred Kunz, Susann Forkel, Jan‐Christoph Simon, Benjamin Klein   +5 more
wiley   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab

Respiratory Medicine Case Reports
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic
Daiki Nakashima, Eri Mori, Nobuyoshi Otori   +2 more
doaj   +1 more source

Dupilumab in the treatment of severe non-control broncial asthma — economic aspects

Качественная клиническая практика, 2019
Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods.
A. S. Salasyuk, M. Yu. Frolov, I. N. Barykina   +2 more
doaj   +1 more source

Serum Eosinophil Level Correlates With Atopic Dermatitis Severity: A Multicenter Cross‐Sectional Study in Chinese Patients With a Nested Cohort Analysis of Dupilumab Treatment Response

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Personalized treatment strategies for atopic dermatitis (AD) are limited. Although serum total IgE (tIgE) and blood eosinophil levels are proposed biomarkers for AD severity, their clinical utility requires validation. Objectives We aimed to identify biomarkers reflecting AD severity and their association with dupilumab efficacy ...
Zhuying Zhang, Jingwen Xue, Yi Zhao
wiley   +1 more source

Case Report: Rare Dupilumab-Associated Pulmonary and Extrapulmonary Tuberculosis [PDF]

Weiyan Xu,1 Jianfeng Zhong2 1Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Department of Infectious Disease, Huzhou Key Laboratory of Precision Medicine Research and Translation ...
Zhong J
core  

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman, Jeffrey Weng, Alysha Vuong, Lawrence Lin, Zhao Feng Liu, Christopher Y. Chew   +5 more
wiley   +1 more source

The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Drug Design, Development and Therapy, 2023
Sarah Balboul,1 Julia Kahn,1 Alexis Tracy,2 Anjelica Peacock,3 Abigail Cline2– 4 1School of Medicine, New York Medical College, Valhalla, NY, USA; 2Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3Department of Dermatology ...
Balboul S, Kahn J, Tracy A, Peacock A, Cline A   +4 more
doaj